Scaling up translational research through the Confidence in Concept (CiC) scheme

Lead Research Organisation: University of Bristol

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50
 
Description Cambridge Cognition: AboutFace 
Organisation Cambridge Cognition Ltd
Country United Kingdom 
Sector Private 
PI Contribution Development of an application to improve emotional face processing in Autism Spectrum Disorder
Collaborator Contribution Collaboration on development and business planning of app
Impact In development. Successful in DPFS at ouline
Start Year 2018
 
Description Evotec: drug to treat genetic forms of Nephrotic Syndrome 
Organisation Evotec
Country Germany 
Sector Private 
PI Contribution pathway to full clinical development of the first drug to treat genetic forms of Nephrotic Syndrome
Collaborator Contribution Material licence signed with Evotec who will repeat our in vitro and in vivo studies to validate results, They may support downstream medicinal chemistry and pre-clinical development
Impact • Domainex subcontracted for protein expression, medicinal chemistry and assay development • Have discussed project under NDA with LifeArc, Evotec, Retrophin, Bridge Bio inc and Goldfinch • Applied for £750,000 Wellcome Innovator Award to develop lead series. • Discussing possible deals with Retrophin and Goldfinch • Material licence signed with Evotec who will repeat our in vitro and in vivo studies to validate results, They may support downstream medicinal chemistry and pre-clinical development • Patent filed
Start Year 2018
 
Description Gene therapy in the kidney - refining a final product for DPFS and first in man studies 
Organisation Syncona
Country United Kingdom 
Sector Private 
PI Contribution Gene therapy in the kidney - refining a final product for DPFS and first in man studies
Collaborator Contribution • In reasonably advanced discussion with Syncona around potential renal gene therapy spin-out. This program (for steroid resistant nephrotic syndrome may be licensed in).
Impact • DPFS submitted but unsuccessful at outline. Panel feedback acknowledged and discussed with Penny Morton. Re-submission planned. • In reasonably advanced discussion with Syncona around potential renal gene therapy spin-out. This program (for steroid resistant nephrotic syndrome may be licensed in). • Offer of co-development and licence deal on table from Retrophin although lack track record in gene therapy. • Positive interaction with MHRA Innovation Office to confirm pre-clinical date requirements. • Also discussed with AstraZeneca (very positive but not an indication they wish to pursue), BridgeBio, Boehringer Ingelheim Venture Fund and AdventLS. • Possible gap funding from Cell and Gene Therapy Catapult Centre and CMO wishing to expand into AAV production.
Start Year 2019
 
Title Ploymeric heart valve 
Description a novel polymeric trans-catheter aortic valve to improve durability in high-risk patients 
IP Reference US2017/0014546 
Protection Patent application published
Year Protection Granted
Licensed No
Impact In development